CHANGZHOU PHARMACEUTICAL FACTORY JIANGSU

Location Clarification:

Please be advised that CHANGZHOU PHARMACEUTICAL FACTORY JIANGSU is located in Changzhou, Jiangsu Province, China, not Singapore. There is no information indicating this specific factory is located or registered as a manufacturing entity in Singapore under this name.

Company Type:

This entity is a manufacturing factory.

Company Profile:

CHANGZHOU PHARMACEUTICAL FACTORY JIANGSU, often referred to as Changzhou Pharmaceutical Factory Co., Ltd. (常州制药厂有限公司), is a well-established pharmaceutical manufacturing enterprise based in Changzhou, Jiangsu Province, China. The company is primarily engaged in the research, development, production, and sales of a diverse range of pharmaceutical products. Its operations encompass the manufacturing of active pharmaceutical ingredients (APIs) as well as various finished dosage forms. As a factory, its core business involves the direct production of medicines, serving both domestic and international markets. The company focuses on quality control and adherence to pharmaceutical manufacturing standards in its production processes.

Changzhou Pharmaceutical Factory Jiangsu is a pharmaceutical manufacturer based in Changzhou, Jiangsu Province, China. It is not a Singaporean company, and it does not typically produce goods directly in Singapore.

The company primarily manufactures and sells a range of pharmaceutical products, including:

Active Pharmaceutical Ingredients (APIs):

Dexamethasone

Prednisone

Hydrocortisone

Betamethasone

Fludrocortisone Acetate

Triamcinolone Acetonide

Finished Pharmaceutical Products:

Various steroid-based medications in forms such as tablets, injections, and topical preparations. These products, manufactured in China, would require specific regulatory approval from the Health Sciences Authority (HSA) to be sold or distributed as finished products in Singapore.

While specific finished products from Changzhou Pharmaceutical Factory Jiangsu that are directly sold in Singapore are not publicly listed, their Active Pharmaceutical Ingredients (APIs) may be supplied to pharmaceutical companies worldwide, including potentially those that manufacture finished dosage forms in or for the Singaporean market.